ROCKVILLE, Md., Nov. 4, 2024
/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it
will participate in the following investor conferences:
UBS Global Healthcare Conference
Fireside
Chat: Wednesday, November 13 at
12:30 p.m. PT
Location: Rancho Palos Verdes,
CA
Stifel 2024 Healthcare Conference
Fireside
Chat: Tuesday, November 19 at
11:30 a.m. ET
Location: New York, NY
Piper Sandler 36th Annual
Healthcare Conference
Fireside Chat:
Thursday, December 5 at 9:30 a.m. ET
Location: New York, NY
Live webcasts of the fireside chats can be accessed in the
Investors section of REGENXBIO's website at www.regenxbio.com. An
archived replay of the webcast will be available for approximately
30 days following the presentation.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. Since its founding in 2009, REGENXBIO has
pioneered the development of AAV Therapeutics, an innovative class
of gene therapy medicines. REGENXBIO is advancing a
pipeline of AAV Therapeutics for rare and retinal diseases,
including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for
the treatment of wet AMD and diabetic retinopathy, being developed
in collaboration with AbbVie, and RGX-121 for the treatment of MPS
II. Thousands of patients have been treated
with REGENXBIO's AAV Therapeutic platform, including
Novartis' Zolgensma® for children with spinal
muscular atrophy. Designed to be one-time treatments, AAV
Therapeutics have the potential to change the way healthcare is
delivered for millions of people. For more information, please
visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-302294648.html
SOURCE REGENXBIO Inc.